Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone

Fertility and Sterility

Volumn 88, Issue 5, 2007, Pages 1382-1388

  Kolibianakis, Efstratios M ^a   Papanikolaou, Evangelos G ^a   Tournaye, Herman ^a   Camus, Michel ^a   Van Steirteghem, Andre C ^a   Devroey, Paul ^a  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

GnRH antagonists; human chorionic gonadotropin; ongoing pregnancy; PCOS; recombinant follicle stimulating hormone

Indexed keywords

CHORIONIC GONADOTROPIN; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE PREGNANCY; OOCYTE MATURATION; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME;

ADULT; CHORIONIC GONADOTROPIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; GONADOTROPIN-RELEASING HORMONE; HUMANS; OOCYTES; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 35248863081     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.12.058     Document Type: Article

References (25)

1. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 81 (2004) 1-5
2. Rizk B., and Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod 6 (1991) 1082-1087
3. D'Angelo A., and Amso N. "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev (2002) CD002811
4. D'Angelo A., and Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev (2002) CD002806
5. Griesinger G., Diedrich K., Devroey P., and Kolibianakis E.M. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 12 (2006) 159-168
6. Abdalla H.I., Ah-Moye M., Brinsden P., Howe D.L., Okonofua F., and Craft I. The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertil Steril 48 (1987) 958-963
7. Shapiro B.S., Daneshmand S.T., Garner F.C., Aguirre M., Ross R., and Morris S. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization. Fertil Steril 84 (2005) 93-98
8. Wikland M., Borg J., Forsberg A.S., Jakobsson A.H., Svalander P., and Waldenstrom U. Human chorionic gonadotrophin self-administered by the subcutaneous route to induce oocyte maturation in an in-vitro fertilization and embryo transfer programme. Hum Reprod 10 (1995) 1667-1670
9. Schmidt D.W., Maier D.B., Nulsen J.C., and Benadiva C.A. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril 82 (2004) 841-846
10. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
11. Kolibianakis E.M., Zikopoulos K., Smitz J., Camus M., Tournaye H., Van Steirteghem A.C., et al. Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod 19 (2004) 1525-1529
12. Kolibianakis E.M., Albano C., Camus M., Tournaye H., Van Steirteghem A.C., and Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 82 (2004) 102-107
13. Kolibianakis E., Zikopoulos K., Albano C., Camus M., Tournaye H., Van Steirteghem A., et al. Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. Reprod Biomed Online 7 (2003) 313-318
14. Van Steirteghem A.C., Nagy Z., Joris H., Liu J., Staessen C., Smitz J., et al. High fertilization and implantation rates after intracytoplasmic sperm injection. Hum Reprod 8 (1993) 1061-1066
15. Devroey P., Tjandraprawira K., Mannaerts B., Coelingh Bennink H., Smitz J., Bonduelle M., et al. A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization. Hum Reprod 10 (1995) 332-337
16. Devroey P., and Van Steirteghem A. A review of ten years experience of ICSI. Hum Reprod Update 10 (2004) 19-28
17. Van Landuyt L., De Vos A., Joris H., Verheyen G., Devroey P., and Van Steirteghem A. Blastocyst formation in in vitro fertilization versus intracytoplasmic sperm injection cycles: influence of the fertilization procedure. Fertil Steril 83 (2005) 1397-1403
18. Blake D., Proctor M., Johnson N., and Olive D. Cleavage stage versus blastocyst stage embryo transfer in assisted conception. Cochrane Database Syst Rev (2005) CD002118
19. Papanikolaou E.G., D'haeseleer E., Verheyen G., Van de Velde H., Camus M., Van Steirteghem A., et al. Live birth rate is significantly higher after blastocyst transfer than after cleavage-stage embryo transfer when at least four embryos are available on day 3 of embryo culture. A randomized prospective study. Hum Reprod 20 (2005) 3198-3203
20. Prien S.D., Canez M.S., and Messer R.H. The dosage of human chorionic gonadotropins influences the relationship between progesterone and cycle outcome during in vitro fertilization-embryo transfer. Int J Fertil Womens Med 45 (2000) 258-263
21. Noyes R.W., Hertig A.J., and Rock J. Dating the endometrial biopsy. Fertil Steril 1 (1950) 3-25
22. Kolibianakis E., Bourgain C., Albano C., Osmanagaoglu K., Smitz J., Van Steirteghem A., et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 78 (2002) 1025-1029
23. Chan C.C., Ng E.H., Tang O.S., Yeung W.S., Lau E.Y., and Ho P.C. A prospective, randomized, double-blind study to compare two doses of recombinant human chorionic gonadotropin in inducing final oocyte maturity and the hormonal profile during the luteal phase. J Clin Endocrinol Metab 90 (2005) 3933-3938
24. Beckers N.G., Macklon N.S., Eijkemans M.J., Ludwig M., Felberbaum R.E., Diedrich K., et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 88 (2003) 4186-4192
25. Elkind-Hirsch K.E., Bello S., Esparcia L., Phillips K., Sheiko A., and McNichol M. Serum human chorionic gonadotropin levels are correlated with body mass index rather than route of administration in women undergoing in vitro fertilization-embryo transfer using human menopausal gonadotropin and intracytoplasmic sperm injection. Fertil Steril 75 (2001) 700-704